TY - JOUR T1 - PARP1/2 imaging with <sup>18</sup>F-PARPi in patients with head and neck cancer JF - medRxiv DO - 10.1101/19009381 SP - 19009381 AU - Heiko Schöder AU - Paula Demétrio De Souza França AU - Reiko Nakajima AU - Eva Burnazi AU - Sheryl Roberts AU - Christian Brand AU - Milan Grkovski AU - Audrey Mauguen AU - Mark P. Dunphy AU - Ronald A. Ghossein AU - Serge Lyashchenko AU - Jason S. Lewis AU - Joseph A. O’Donoghue AU - Ian Ganly AU - Snehal G. Patel AU - Nancy Y. Lee AU - Thomas Reiner Y1 - 2019/01/01 UR - http://medrxiv.org/content/early/2019/11/02/19009381.abstract N2 - Purpose We performed a first-in-human clinical trial. The aim of this study was to determine safety and feasibility of PET imaging with 18F-PARPi in patients with head and neck cancer.Patients and Methods Eleven patients (age 49 to 86 years) with newly diagnosed or recurrent oral and oropharyngeal cancer were injected intravenously with 18F-PARPi (331 ± 42 MBq) and dynamic PET/CT imaging was performed between 0 min and 25 min post-injection. Static PET/CT scans were obtained at 30 min, 60 min and 120 min p.i. Blood samples for tracer concentration and metabolite analysis were collected. Blood pressure, ECG, oxygen levels, clinical chemistry and CBC were obtained before and after administration of 18F-PARPi.Results 18F-PARPi was well-tolerated by all patients without any safety concerns. Of the 11 patients included in the analysis, 18F-PARPi had focal uptake in all primary lesions (n = 10, SUVmax = 2.8 ± 1.2) and all 18F-FDG positive lymph nodes (n = 34). 18F-PARPi uptake was seen in 18F-FDG negative lymph nodes of three patients (n = 6). Focal uptake of tracer in primary and metastatic lesions was corroborated by CT alone or in combination with 18F-FDG. Contrast for 18F-PARPi and 18F-FDG was comparable (SUVmax(lesion)/SUVmax(genioglossus) = 3.3 and 3.0, respectively; p = 0.23), and SUVmax values for 18F-PARPi were less variable compared to 18F-FDG (1.3 versus 6.0, p = 0.001).Conclusions Imaging of head and neck cancer with 18F-PARPi is feasible and safe. 18F-PARPi detects primary and metastatic lesions, and retention in tumors is longer than in healthy tissues.Competing Interest StatementS.P., C.B., J.S.L. and T.R. are shareholders of Summit Biomedical Imaging, LLC. S.P. and T.R. are co-inventors on filed U.S. patent (WO2016164771) that covers methods of use for PARPi-FL. T.R. is co-inventor on U.S. patents (WO2012074840 and WO2016033293), covering the compositions of matter for PARPi-FL and 18F-PARPi, respectively. T.R. is a paid consultant for and has received grant support from Theragnostics, Inc., which has licensed 18F-PARPi. This arrangement has been reviewed and approved by Memorial Sloan Kettering Cancer Center in accordance with its conflict of interest policies.Clinical TrialNCT03631017Funding StatementThis work was supported in part by National Institutes of Health grants R01 CA204441, R35 CA232130 and P30 CA008748, the Tow Foundation, the MSK Center for Molecular Imaging * Nanotechnology, the MSK Imaging and Radiation Sciences Program and the MSK Molecularly Targeted Intraoperative Imaging Fund.Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.YesI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.YesSupplementary data is available online or from the corresponding authors. ER -